Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia
| Autor: | Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, Jeff Klaus |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Daunorubicin Secondary AML 03 medical and health sciences 0302 clinical medicine High dose cytarabine hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols polycyclic compounds medicine Humans Secondary Acute Myeloid Leukemia In patient neoplasms Retrospective Studies business.industry organic chemicals Cytarabine Hematology Liposomal daunorubicin carbohydrates (lipids) Leukemia Myeloid Acute 030220 oncology & carcinogenesis FLAG (chemotherapy) business 030215 immunology medicine.drug |
| Zdroj: | Leukemia & Lymphoma. 62:2184-2192 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2021.1907378 |
| Popis: | Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 against regimens containing a purine analogue and high-dose cytarabine (HIDAC). This retrospective study compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based regimens and CPX-351 in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% in the HIDAC-based therapy arm vs. 47.9% in the CPX-351 arm ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |